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Marcel R. M. van den Brink,1 David L. Porter,2 Sergio Giralt,3 Sydney X. Lu,1 Robert R. Jenq,1
Alan Hanash,1 Michael R. Bishop4Disease relapse remains a major cause of mortality following allogeneic hematopoietic cell transplantation
(HCT). Over the past decade, our understanding of the biology underlying the graft-versus-tumor/leukemia
(GVT) effect has increased greatly; however, several other factors affect the occurrence and outcome of
relapse, including conditioning regimen, type of allograft, and the histology, status, and sensitivity to chemo-
therapy of the disease being treated. The mainstay of relapse treatment is donor lymphocyte infusion (DLI),
but the efficacy of DLI is quite variable depending on disease histology and state. As such, there is a significant
need for novel therapies and strategies for relapse following allogeneic HCT, particularly in patients for
whom DLI is not an option. The National Cancer Institute is sponsoring an international workshop to ad-
dress issues and research questions relative to the biology, natural history, prevention, and treatment of re-
lapse following allogeneic HCT.
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In his 1975 review of bone marrow transplantation
(BMT) in theNew England Journal ofMedicine, E. Don-
nall Thomas noted that the major barriers to the
successful application of this modality were the avail-
ability of suitable donors, treatment-related toxicities,
and relapse of disease [1]. The past 30 years have seen
tremendous progress in addressing the need for donors
for allogeneic hematopoietic cell transplantation
(HCT) through the use of volunteer HLA-matched
unrelated donors (MUDs), haploidentical related
donors, and cord blood units (CBUs) [2]. There also
have been significant improvements in supportive
care measures, with better agents to treat mucositis
and a marked increase in the number and efficacy
of antibiotics to treat bacterial, viral, and fungal
infections. Nonmyeloablative (NMA) and reduced-
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6/j.bbmt.2009.10.023introduced, which have been associated with as much
as a 50% reduction in treatment-related mortality
(TRM), compared with myeloablative (MA) condi-
tioning in similar patient populations [3,4].
Despite these advances, however, there has been
very little progress in reducing the incidence of relapse
following allogeneic HCT and in improving the sub-
sequent outcomes of patients who experience relapse,
which remains one of the leading causes of death
following allogeneic HCT (Figure 1). This limited
improvement has occurred despite our improved
understanding of the biology underlying the graft-
versus-tumor/leukemia (GVT) effect [5] and, more
importantly, the introduction of donor lymphocyte in-
fusion (DLI) as a therapeutic option for patients expe-
riencing disease progression or relapse after allogeneic
HCT [6]. Relative to the biology underlying the GVT
effect, or understanding of the major interactions
among various lymphocytes (eg, T regulatory cells,
natural killer [NK] cells), antigens (eg, WT1, PR1)
receptors (eg, killer cell immunoglobulin-like recep-
tors [KIR]), cytokines (eg, interleukin [IL]-2, IL-7,
IL-15, transforming growth factor b-1), and the tumor
environment in mediating the GVT effect has im-
proved [7]. But, despite this greater understanding,
we have been able to translate these findings into sig-
nificant improvements in outcomes in only a minority
of patients [8]. With regard to DLI, in the disease for
which it is most effective—chronic myelogenous leu-
kemia (CML)—allogeneic HCT is performed only in
patients who are resistant to tyrosine kinase inhibitors.
In the vast majority of malignant diseases for which
Figure 1. Causes of death following allogeneic HCTas reported to the CIBMTR.
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can provide long-term disease-free survival (DFS) for
only a minority of patients [9]. These results are even
more disappointing when viewed in the context of
a significantly increased risk of relapse in individuals
who undergo allogeneic HCT following NMA condi-
tioning or RIC.
Most of the available medical literature on relapse
following allogeneicHCT focuses on treatment, partic-
ularly on immunotherapeutic approaches, such as with-
drawal of immune suppression and DLI. An important
clinical question is what should be done with patients
with active graft-versus-host disease (GVHD), for
whom DLI is relatively contraindicated. There are rel-
atively few reports on nonimmunologic treatments, de-
spite the fact that sensitivity to chemotherapy is
commonly cited as the most important prognostic fac-
tor associated with relapse. Other important factors af-
fecting relapse include histology, disease state, stem cell
source, graft manipulation, immunosuppression, and,
as mentioned earlier, conditioning regimen. There is
a paucity of data on the epidemiology, prevention, and
monitoring for relapse of various diseases after alloge-
neic HCT. Unfortunately, the disease for which there
are the most data is CML. This can serve as a model
for studying relapse in other diseases, however. In this
brief review, we provide an overview of the current un-
derstanding of the GVT effect and treatment ap-
proaches, and also call on the transplantation
community to address the major laboratory and clinical
questions related to relapse following allogeneic HCT.T CELLS IN THE GRAFT-VERSUS-TUMOR
RESPONSE
Although the conditioning regimen remains an
important contributor to the antitumor potential ofallogeneic HCT, recently the therapeutic effect of
GVT activity has been emphasized. Extensive analysis
in both human and animal studies has shown that
GVT activity is mediated primarily by T cells and
NK cells, although other cells also can contribute
through direct or indirect mechanisms. In some cases,
donor T cells can recognize a tumor-specific antigen
(eg, Bcr/Abl in CML) or a minor histocompatibility
antigen, such as a polymorphic antigen with restricted
expression on hematopoietic cells (eg, HA-1/2); how-
ever, the major contributors to theGVT activity of do-
nor T cells are likely alloreactive T cells recognizing
alloantigens on tumor cells and normal tissue cells in
the recipient. Clinical studies support this notion and
have demonstrated an inverse correlation between
GVHD (especially chronic GVHD [cGVHD]) and
the risk of posttransplantation relapse. Thus, strategies
to enhance GVT activity could result in worsening
GVHD, and novel approaches to improve GVT
must be evaluated for this potential complication.
Here we briefly review selected approaches for en-
hancing GVT without exacerbating GVHD. Recent
reviews of strategies to promote GVT without exacer-
bating GVHD are listed in Table 1 [10-15].Posttransplantation Environment
Recent studies have resulted in a new appreciation
of the posttransplantation setting as a unique environ-
ment that seems to be conducive to T cell reactivity
against tumor cells as well as vaccines aimed at en-
hanced T cell responses. Recently, investigators study-
ing optimal conditions for cancer immunotherapy
‘‘reinvented’’MA conditioning followed by autologous
HCT as an ideal setting for adoptive T cell therapies
[16]. Posttransplantation infusion of T cells can pro-
duce robust T cell expansion, and vaccines and im-
mune-modulating antibodies also appear to have
Table 1. T Cell Approaches to Enhancing GVT without
Exacerbating GVHD
Strategy Reference
Immune reconstitution [10]
Cytolytic pathways [11]
Trafficking [12]
Regulatory T cells [13]
Effector memory T cells [14]
Adoptive cell therapy and vaccines [15]
GVT indicates graft-versus-tumor/leukemia; GVHD, graft-versus-host
disease.
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phocytes. Possible mechanisms include increased ac-
cess to antigen-presenting cells (APCs; and major
histocompatibility complex [MHC]/antigen), in-
creased access to cytokines (eg, IL-2, IL-7, IL-15,
IL-21), decreased suppressor cell populations, lym-
phopenia-induced homeostatic proliferation of naı¨ve
T cells, and radiation-induced up-regulation of traf-
ficking/adhesion molecules and costimulatory mole-
cules and activation of dendritic cells [17,18].T Cell Reconstitution
Patients undergoing allogeneic HCT experience
prolonged posttransplantation deficiencies in T cell
numbers and function, associated with increased risk
for malignant relapse, development of secondary ma-
lignancies, and suboptimal response to immunothera-
peutic strategies, such as antitumor vaccination.
Currently, the most promising approaches to enhanc-
ing posttransplantation T cell reconstitution include
cytokines and growth factors, including growth hor-
mone, insulin-like growth factor I, ghrelin, sex steroid
ablation with leuprolide, keratinocyte growth factors,
IL-7, IL-12, and IL-15. All of these agents have shown
promise in animal models, and most are currently in
early clinical trials [19].T Cell Cytolysis
Cytotoxic T cells execute their function via the
perforin/granzyme system and death receptor ligands
(eg, FasL, tumor necrosis factor [TNF]-related apo-
ptosis-inducing ligand [TRAIL], TNF-like weak in-
ducer of apoptosis [TWEAK]), which trigger the
target cell’s own apoptotic pathways [11]. Multiple
murine models have demonstrated differential use of
these cytolytic pathways during GVT and target organ
GVHD; for example, FasL is important for liver
GVHD, whereas TNF plays a critical role in intestinal
GVHD. Depending on the tumor model used, each of
these pathways can be involved in GVT activity,
althoughGVT activity by TWEAK has not been stud-
ied to date. Overexpression of TRAIL in T cells seems
to be able to enhance GVT activity against certain
malignancies, although TRAIL has been recentlyimplicated in thymic GVHD (M.vdB., unpublished
observations).
T Cell Trafficking
Studies in mouse models have demonstrated roles
for individual selectins, integrins, and chemokines/
chemokine receptors in the pathogenesis of GVHD
[12]. For example, donor T cells deficient for CCR2
or b7 integrin have decreased capability to home to
the liver and gastrointestinal (GI) tract, resulting in
decreased GVHD, but intact GVT responses. Natali-
zumab is a humanized antibody to the a4 subunit of
certain integrin heterodimers, including a4b7, which
is associated with homing to the intestines. Natalizu-
mab has been tested for use in inflammatory bowel dis-
ease and multiple sclerosis and might be useful for
inhibiting migration to GVHD target tissues while
still permitting activation of GVT effectors in lym-
phoid tissue. But, further studies with natalizumab
are complicated by a controversy regarding the in-
creased risk of progressive multifocal leukoencephal-
opathy observed in patients treated with this drug.
Regulatory T Cells
Various investigators have demonstrated in mouse
models that regulatory T cells (Tregs) of donor or host
origin can inhibit GVHD. CD41CD251 Tregs sup-
press the early expansion of alloreactive donor T cells
and have been reported to limit their expression of IL-
2 receptor (IL-2R) alpha-chain and their capacity to
induce GVHD without abrogating GVT effector
function, which is mediated primarily by the perforin
lysis pathway. Thus, at least in mouse models, donor
Tregs can separateGVHD fromGVT activity. Several
clinical studies of Treg administration in patients
undergoing allogeneic HCT are currently underway.
Effector Memory T Cells
On encountering their cognate antigen in the con-
text of appropriate costimulatory signals, naı¨ve CD81
T cells will become activated and can develop into
effector (TEM) and central memory (TCM) CD8
1 T
cells. Similar differentiation patterns have been pro-
posed for CD41 T cells. TCM cells are long-lived
and express CD62L and CCR7, in contrast to CD81
TEM cells. Studies in mouse models have shown that
selected CD41 or CD81 donor TEM (as opposed to
naı¨ve) T cells cause less GVHD, but can still exert
GVT activity. Several investigators are currently plan-
ning clinical trials in allogeneic HCT recipients with
selected donor TEM cells.
Adoptive Cell Therapy and Vaccines
Beginning with DLI, the potential of adoptive T
cell therapy has been widely recognized as a way to en-
hance GVT activity and prevent or treat malignant
Biol Blood Marrow Transplant 16:S138-S145, 2010 S141Relapse after Allogeneic HCTrelapse. Various strategies focusing on the ex vivo ex-
pansion of donor T cells that can recognize one or
more antigens on tumor cells have been developed.
These cells can be modified with suicide genes (to
halt the development of GVHD), modified with spe-
cific T cell receptors (TCRs) resulting in T cells with
dual TCRs, chimeric antigen receptors, which use
the antigen-binding portion of an antibody in combi-
nation with the TCRz chain for activation. The cells
can also be made undergo ex vivo polarization toward
Th1 or Th17 or altered with various other strategies.
Several of these approaches are currently in clinical
trials as upfront or delayed adoptive T cell therapy in
allogeneic HCT recipients.
In this review, we can touch on only a few of the
many exciting strategies being developed to enhance
T cell-mediated GVT. Many issues remain to be ad-
dressed, ranging from feasibility to financial costs to
scientific issues. For example, the ‘‘Achilles heel’’ of
T cells is their requirement of antigen recognition,
when many tumor cells, through genetic instability
and various other mechanisms, can down-regulate
many potential antigens and avoid elimination by T
cells. Thus, an important question for any potential
tumor target antigen is whether its expression is indis-
pensable for the survival of the tumor cells. Alterna-
tively, the GVT activity of T cells could be directed
against noncancer cells in the tumor stroma, such as
tumor vasculature myeloid-derived suppressor cells.
However, as our understanding of T cell biology con-
tinues to grow, new approaches to optimizingGVT ef-
fects by T cells, which remain the most important
mediators of GVT, can be expected.STRATEGIES AND OPTIONS FOR
RECURRENT DISEASE FOLLOWING
ALLOGENEIC HCT
Treatment options for most patients who relapse
after allogeneic HCT are limited, and prognosis is
generally poor, with the exception of CML. In general,
the greatest potential for successful treatment of re-
lapse is manipulation or enhancement of donor cells
as GVT induction. Thus, the most common interven-
tion for relapse is DLI. In some cases, supportive and
palliative care may be the most appropriate option.
Disease-specific chemotherapy or radiation can be
considered in some settings, but this carries poor
long-term survival [20]. In some cases, cytokines to ac-
tivate T, NK, or dendritic cells have resulted in sus-
tained remission after relapse. A second HCT may
be curative, but is associated with extensive morbidity
and mortality. Ultimately, newer strategies are needed
to maximize efficacy and limit toxicity when treating
relapse after allogeneic HCT.Withdrawal of Immunosuppression
To maximize the GVT activity, withdrawal of
immunosuppression is often the first intervention for
relapse. Although numerous anecdotal successes have
been reported, this approach by itself is rarely effective
in patients with diseases other than CML.Second Allogeneic HCT
Historically, the role of second allogeneic HCT
has been limited by unacceptable relapse rates and
high mortality. TRM is between 25% and 45% after
MA second transplantation and varies from 0 to 30%
after NMA second transplantation, depending on pre-
vious therapies, age, and time from first transplanta-
tion. Relapse rates are disease-dependent, but few
studies report a relapse rate\ 40%. However, most
studies include only a small number of patients and
are underpowered to make definitive conclusions. In-
terestingly, despite this high risk, survival rates after
a secondMA transplantation for acute leukemia are re-
portedly between 25% and 40% (although clearly this
represents highly selected patients). Available data do
not support a benefit with a second donor and gener-
ally demonstrate improved outcomes for younger pa-
tients and a longer time (. 6-12 months) from
transplantation to relapse. Data from the Center for
International Blood and Marrow Transplant Research
(CIBMTR) show a 5-year survival rate of 51% in pa-
tients under age 20 years who relapsed more than 6
months after transplantation (95% confidence interval
[CI] 5 38%-62%) and only 3% (95% CI 5 0.02%-
12%) in older patients who relapsed within 6 months
after transplantation (Figure 2) [21]. The European
Group for Blood and Marrow Transplantation
(EBMT) reported the best outcomes for patients
with late relapse (. 292 days) in remission at time of
second transplantation, with 53% survival at 3 years
[22]. Statistically significant predictors of better sur-
vival were relapse more than 292 days after transplan-
tation (hazard ratio [HR] 5 0.5; 95% CI 5 0.35-0.74;
P 5 .0001), complete remission (CR) at second HCT
(HR 5 0.67; 95% CI 5 0.46-0.97; P 5 .0001), and use
of total body irradiation (TBI) with secondHCT (HR5
0.5; 95% CI 5 0.35-0.74; P 5 .001).
The use of RIC for a second allogeneic HCT is ex-
pected to minimize TRM, but relapse rates are high.
Nevertheless, long-term survival rates of 20% to
60% have been reported. Outcome depends on many
factors, including the intensity of the first and second
conditioning regimens, time to relapse, underlying
disease, and disease status at transplantation. Whether
or not an RIC regimen improves outcome compared
with conventional conditioning for a second allogeneic
HCT is unknown.
Figure 2. Second allogeneic HCT as reported to the CIBMTR [21].
Probability of overall survival after second transplantation. A, Age
#20 years; duration of remission. 6 months. B, Age. 20 years; dura-
tion of remission. 6months. C, Age#20 years; duration of remission 6
months. D, Age . 20 years; duration of remission #6 months.
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Relapsed CML
DLI for relapsed CML is dramatically effective and
induces molecular CR in up to 80% of patients who re-
lapse in the chronic phase (CP) [23]. These remissions
are sustained in the majority of patients, although late
relapses raise the concern that GVT effects might
have a limited life span or that the primitive leukemic
stem cell may not be eradicated.
Imatinib may be an effective alternative to DLI for
relapsed CML without the risk of GVHD in patients
who have not been previously treated or developed re-
sistance to this drug. Limited data suggest that up to
70% of patients achieve a molecular CR. It appears
that continued therapy is necessary to prevent progres-
sion [24]. Whether second-generation tyrosine kinase
inhibitors (TKIs), such as dasatinib or nilotinib, will
be more effective than imatinib for relapsed CML is
not known. In the modern era, most patients proceed
to HCT only after developing imatinib resistance,
but may remain sensitive to newer agents. It is not
known, but it seems unlikely, that patients who proceed
to HCT because of resistance to multiple TKIs would
benefit from this therapy.
Although combined TKI and cellular therapy has
not been prospectively studied, the combination of im-
atinib or another TKI with DLI has the advantage of
affording a rapid reduction in leukemia burden and
disease control until an effective immune response
can develop. Moreover, it is possible that lower T
cell doses can be used, thus reducing the risk of
GVHD. Unfortunately, DLI is less effective for pa-
tients with accelerated and blast-phase CML; only
12% to 28% of these patients achieve remission, and
many responses are transient.
WhenDLI and TKI therapy are not options or are
ineffective, interferon-a may be a useful alternative
[25]. Vaccine strategies also hold particular promise
for relapse of indolent diseases like CML [26].Acute Leukemias
For relapsed acute leukemias, both conventional
chemotherapy and newer biological agents result in
significant remission rates, but poor long-term sur-
vival. The use of novel agents (eg, dasatinib or a newer
TKI) in patients with Ph1 acute lymphoblastic leuke-
mia (ALL) or 5-azacytidine for relapsed acute myelog-
enous leukemia (AML) may have particular benefit.
Sorafenib, a multikinase inhibitor, has demonstrated
preliminary activity in a small number of patients
with relapsed FLT31 AML [27].
For patients with relapsed ALL, outcomes are par-
ticularly poor after DLI, with response rates of 0% to
20% and overall survival rates of\15% [9]. Outcomes
after DLI for relapsed AML are more variable. Re-
sponse occurs in 15% to 30% of patients, but remis-
sions generally are of short duration, and long-term
survival is only approximately 20%. The EBMT stud-
ied outcomes in almost 400 patients with relapsed
AML [28]. In the 171 patients who receivedDLI, those
patients who achieved remission by other means dem-
onstrated improved outcomes. In a good-risk popula-
tion of patients in remission with a favorable
karyotype, the 2-year overall survival (OS) was 56%.
In contrast, patients who received DLI during active
disease or aplasia had an OS of 9% to 20% (overall
15%), depending on other risk factors. Nevertheless,
patients treated with DLI appear to have better
outcomes than those who never receive DLI (OS of
21% vs 9% at 2 years). Furthermore, patients who
relapse later after allogeneic HCT and receive DLI
have improved outcomes compared with those who
relapse early [29].
Immunotherapy often fails because rapid leukemia
cell growth may outpace the cytotoxicity of donor leu-
kocytes. CR is more common in patients with acute
leukemia who receive given chemotherapy before
DLI (c-DLI). One study reported CR in 47% of pa-
tients [29]. Although OS at 2 years was 19%, patients
who recovered from c-DLI in CR had 1- and 2-year
survival rates of 51% and 41%, respectively, compared
with a 1-year survival of 5% in nonresponders. Survival
at 1 year for patients with relapse occurring less than 6
months after transplantation was 10%, compared with
44% for patients who relapsed more than 6 months af-
ter transplantation (P\ .001).DLI for Myeloma, Hodgkin Disease,
Non-Hodgkin Lymphoma, and Chronic
Lymphocytic Leukemia
Response rates and remission duration following
DLI in other diseases are less well defined. It is clear
that a ‘‘graft-versus-myeloma’’ effect fromDLI can in-
duce remission in some patients who relapse after allo-
geneic HCT, but relapse rates are high and long-term
outcomes are poor [30]. The use of newer biological
Table 2. Newer Approaches to Cellular Therapies to Treat
Relapse
 Combined chemotherapy and biological therapy with DLI (eg, imatinib, 5-
azacytadine, gemtuzumab, bispecific antibodies)
 Ex vivo activation and expansion of donor T cells through costimulation
 Generation and infusion of tumor-specific T cells
 Generation and infusion of minor histocompatibility antigen-specific T
cells
 Low-dose DLI followed by dose escalation
 Infusion of selected T cell subsets (ie, after CD8+ cell depletion or CD4+
cell selection)
 Inactivation of alloreactive T cells (ie, through transduction of suicide
genes into donor T cells, photochemical inactivation, chemotherapy
inactivation, or irradiation)
 Infusion of T regulatory cells
 Generation and infusion of Th2-type T cells
 Generation of other cellular effectors, such as NK and dendritic cells
 Manipulation of antigen-presenting cells to maximize GVTor minimize
GVHD
 Administration of tumor-specific vaccines (eg, antigen-specific, modified
tumor cells) combined with cellular effectors
 Recruitment of T cells to tumor through use of modified T cells expressing
chimeric antigen receptors or using bispecific antibodies
DLI indicates donor lymphocyte infusion; GVHD, graft-versus-host dis-
ease.
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expand treatment options, not only for patients with
relapsedmyeloma, but also for those with chronic lym-
phocytic leukemia (CLL) and non-Hodgkin lym-
phoma (NHL). Data on outcomes after DLI for
relapsed NHL, CLL, and Hodgkin disease (HD) are
relatively limited; however, experience demonstrates
that a meaningful graft-versus-lymphoma reaction
can be generated after DLI for NHL and HD
[9,31,32]. Graft-versus-lymphoma activity and re-
sponses to DLI seems to be most active in patients
with indolent lymphoma, mantle cell lymphoma
(MCL), and CLL. Newer antibodies designed either
to directly target tumor cells or to recruit T cells di-
rectly to sites of disease also hold promise for relapsed
patients [33].
Relapse after RIC Transplantation
As noted earlier, RIC is associated with higher re-
lapse rates compared with MA conditioning before al-
logeneic HCT. Whereas mortality is quite high in
patients who relapse after RIC HCT, patients who re-
ceive therapy seem to have better outcomes than those
who do not [34]. Response rates to DLI after RIC al-
logeneic HCT are similar to those after conventional
allogeneic HCT.
New Approaches to Treating Relapse
Despite the achievements with DLI, high response
rates are largely limited to CML and are tempered by
significant GVHD and other toxicities. Innovative and
novel immunotherapeutic approaches are currently
under investigation (Table 2). Among other ap-
proaches, nonspecific ex vivo activation and expansion
through costimulation of donor T cells have been used
safely, with intriguing GVT responses [35]. It also may
be possible to generate leukemia-specific cytotoxic T
cells to use in adoptive immunotherapy [36]. Target-
ing cytotoxic T cells to tumor cells through gene
modification with chimeric antigen receptors or bi-
functional antibodies are other exciting, essentially un-
explored therapies [33,37]. Vaccine strategies with
tumor-specific antigens or modified tumor cells are
other promising approaches to generating tumor-
specific immunity [26,38]. These strategies will likely
be most effective in the setting of minimal disease.
CombiningDLI with antibody therapy that may direct
effector cells directly to tumor cells may overcome
possible resistance mechanisms to GVT induction
without excessive toxicity.
Because DLI seems to be the most effective for pa-
tients with minimal disease, the role of prophylactic
DLI for patients in remission needs to be better de-
fined. If donor T cells become tolerant or possibly rap-
idly senescent after HCT as a mechanism leading to
relapse, then the use of repetitive DLI once a patientachieves remission may be useful [39]. In addition,
the role of other cell populations (eg,NK and dendritic
cells [DCs]) in GVT induction for relapse needs to be
explored in more detail. Ultimately, understanding the
biology of relapse and mechanisms involved in GVT
induction will permit more effective and patient-
specific approaches for relapsed disease.
Alternatives to cellular therapies for treating re-
lapse must be considered as well. The use and study
of conventional and novel agents has been hindered
by the widely differing dosing regimens and toxicity
profiles in HCT recipients. Outcome depends on pre-
vious therapy, disease activity, time of relapse, GVHD
and other coincident toxicities, and many other fac-
tors. Typical dosing regimens and treatment schemes
may vary widely. Evaluation of immunologic effects
in addition to disease outcomes is needed to make
progress in managing disease relapse. Well-designed
clinical trials in specific diseases will be needed to ex-
plore the activity of and role for these therapies, partic-
ularly in situations in which cellular therapies have
been ineffective. Given the very high-risk nature of
these patients, it will be critical to engage not just the
transplantation community, but also pharmaceutical
manufacturers and regulatory agencies to rapidly
address the unique issues posed by this patient
population.FIRST INTERNATIONALWORKSHOPONTHE
BIOLOGY, PREVENTION, AND TREATMENT
OF RELAPSE AFTER ALLOGENEIC HCT
To address the problem of relapse following allo-
geneic HCT, the National Cancer Institute convened
a workshop in Bethesda, Maryland, on November 2
S144 Biol Blood Marrow Transplant 16:S138-S145, 2010M. R. M. van den Brink et al.and 3, 2009. Planning began in 2008, with the primary
objectives of (1) reviewing the current ‘‘state of the sci-
ence’’ relative to the biology, natural history, preven-
tion, and treatment of relapse following allogeneic
HCT; (2) identifying the most important questions
and problems related to the biology, prevention, and
treatment of relapse following allogeneic HCT over
the next 5 years; (3) providing specific recommenda-
tions as to what studies and resources are needed to
answer these questions and providing for the deficits
relative to the research related to relapse following
allogeneic HCT; and (4) providing a forum for inter-
ested researchers to interact and form networks of in-
terest. An international group of more than 60 basic
and clinical researchers was assembled and assigned
to specific committees addressing the biology, strate-
gies, and therapies for prevention, disease-specific
monitoring methods and strategies, and disease-spe-
cific treatment of relapse following allogeneic HCT.
Each committee generated a list of research priorities,
and presented a summary of their recommendations
for open discussion at the workshop. The final recom-
mendations will be published sequentially in Biology
of Blood and Marrow Transplantation. At the end of the
2-day workshop, an executive summary report from
all of the working committees was developed for sub-
sequent publication. A summary of the workshop rec-
ommendations will be presented at the 2010 Tandem
Transplant Meetings Educational Sessions.ACKNOWLEDGMENTS
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